TMEM47

Summary

TMEM47 (transmembrane protein 47, HGNC:18515) is a protein-coding gene on chromosome Xp21.1, encoding Transmembrane protein 47 (Q9BQJ4). Regulates cell junction organization in epithelial cells.

This gene encodes a member of the PMP22/EMP/claudin protein family. The encoded protein is localized to the ER and the plasma membrane. In dogs, transcripts of this gene exist at high levels in the brain.

Source: NCBI Gene 83604 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 26 total — 1 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_031442

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18515
Approved symbol	TMEM47
Name	transmembrane protein 47
Location	Xp21.1
Locus type	gene with protein product
Status	Approved
Aliases	BCMP1, DKFZP761J17121, DKFZp564E153, VAB-9
Ensembl gene	ENSG00000147027
Ensembl biotype	protein_coding
OMIM	300698
Entrez	83604

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000275954, ENST00000876538

RefSeq mRNA: 1 — MANE Select: NM_031442 NM_031442

CCDS: CCDS14235

Canonical transcript exons

ENST00000275954 — 3 exons

Exon	Start	End
ENSE00000978421	34639247	34639387
ENSE00001163631	34627075	34630491
ENSE00001321415	34656804	34657285

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 99.67.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.6822 / max 110.7990, expressed in 1052 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
198867	5.3326	983
198865	0.3096	147
198866	0.3065	123
198864	0.2837	87
198869	0.2707	133
198868	0.1791	63

Top tissues by expression

300 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
choroid plexus epithelium	UBERON:0003911	99.67	gold quality
saphenous vein	UBERON:0007318	99.60	gold quality
urethra	UBERON:0000057	99.34	gold quality
blood vessel layer	UBERON:0004797	99.26	gold quality
vena cava	UBERON:0004087	98.74	gold quality
seminal vesicle	UBERON:0000998	98.67	gold quality
superficial temporal artery	UBERON:0001614	98.46	gold quality
cranial nerve II	UBERON:0000941	98.08	gold quality
superior vestibular nucleus	UBERON:0007227	98.05	gold quality
cauda epididymis	UBERON:0004360	97.99	gold quality
diaphragm	UBERON:0001103	97.58	gold quality
CA1 field of hippocampus	UBERON:0003881	97.48	gold quality
right coronary artery	UBERON:0001625	97.46	gold quality
visceral pleura	UBERON:0002401	97.44	gold quality
cardiac muscle of right atrium	UBERON:0003379	97.33	gold quality
dorsal root ganglion	UBERON:0000044	97.31	gold quality
ascending aorta	UBERON:0001496	97.27	gold quality
thoracic aorta	UBERON:0001515	97.27	gold quality
cardia of stomach	UBERON:0001162	97.19	gold quality
aorta	UBERON:0000947	97.16	gold quality
pericardium	UBERON:0002407	97.13	gold quality
pylorus	UBERON:0001166	97.12	gold quality
pleura	UBERON:0000977	97.09	gold quality
popliteal artery	UBERON:0002250	97.07	gold quality
parietal pleura	UBERON:0002400	97.07	gold quality
tibial artery	UBERON:0007610	97.06	gold quality
caput epididymis	UBERON:0004358	96.97	gold quality
descending thoracic aorta	UBERON:0002345	96.92	gold quality
artery	UBERON:0001637	96.83	gold quality
mammary duct	UBERON:0001765	96.81	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-HCAD-10	yes	35.67
E-GEOD-135922	yes	24.68
E-MTAB-7316	yes	21.93
E-GEOD-81608	yes	8.92
E-HCAD-11	yes	7.75
E-ANND-3	yes	5.50
E-GEOD-83139	yes	4.33
E-GEOD-124858	no	513.85
E-ENAD-27	no	3.32

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F1, FOXO1

miRNA regulators (miRDB)

271 targeting TMEM47, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754

Literature-anchored findings (GeneRIF, showing 6)

• A 4-transmembrane protein, related to PMP22/EMPs and the Claudins, localizes to the plasma membrane and the ER. The mRNA is present in high amounts in brain. (PMID:11472633)
• Single nucleotide polymorphisms, but no disease-associated mutations, were identified in X-linked mental retardation patients. (PMID:15345028)
• TM4SF10, possibly through ADAP, may regulate Fyn activity (PMID:21881001)
• TMEM147 interacts with lamin B receptor, regulates its localization and levels, and affects cholesterol homeostasis. (PMID:32694168)
• Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma. (PMID:32945373)
• Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells. (PMID:33745390)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmem47	ENSDARG00000057322
mus_musculus	Tmem47	ENSMUSG00000025666
rattus_norvegicus	Tmem47	ENSRNOG00000030418
drosophila_melanogaster	CG45049	FBGN0266409
caenorhabditis_elegans		WBGENE00006875

Paralogs (1): PERP (ENSG00000112378)

Protein

Protein identifiers

Transmembrane protein 47 — Q9BQJ4 (reviewed: Q9BQJ4)

Alternative names: Brain cell membrane protein 1, Transmembrane 4 superfamily member 10

All UniProt accessions (1): Q9BQJ4

UniProt curated annotations — full annotation on UniProt →

Function. Regulates cell junction organization in epithelial cells. May play a role in the transition from adherens junction to tight junction assembly. May regulate F-actin polymerization required for tight junctional localization dynamics and affect the junctional localization of PARD6B. During podocyte differentiation may negatively regulate activity of FYN and subsequently the abundance of nephrin.

Subunit / interactions. Interacts with CTNNB1, CTNNA1, PRKCI, PARD6B, FYB1.

Subcellular location. Membrane. Cell junction. Adherens junction.

Tissue specificity. Expressed in adult brain, fetal brain, cerebellum, heart, lung, prostate and thyroid.

Similarity. Belongs to the TMEM47 family.

RefSeq proteins (1): NP_113630* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004031	PMP22/EMP/MP20/Claudin	Family
IPR015664	P53_induced	Family

Pfam: PF00822

UniProt features (7 total): transmembrane region 4, initiator methionine 1, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BQJ4-F1	86.19	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 215 (showing top): TAATAAT_MIR126, MODULE_255, TTTGTAG_MIR520D, MODULE_317, TATTATA_MIR374, USF_C, CCATCCA_MIR432, SRF_Q5_01, EVI1_05, MODULE_66, GOBP_CELL_CELL_ADHESION, DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_UP, CAGCAGG_MIR370, SRF_C, WTGAAAT_UNKNOWN

GO Biological Process (1): cell-cell adhesion (GO:0098609)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): plasma membrane (GO:0005886), cell-cell junction (GO:0005911), adherens junction (GO:0005912), membrane (GO:0016020), anchoring junction (GO:0070161)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell adhesion	1
binding	1
membrane	1
cell periphery	1
anchoring junction	1
cell-cell junction	1
cellular anatomical structure	1
cell junction	1

Protein interactions and networks

STRING

984 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM47	AJM1	C9J069	722
TMEM47	FAM47B	Q8NA70	581
TMEM47	CDH17	Q12864	529
TMEM47	TMEM94	Q12767	480
TMEM47	FAM110C	Q1W6H9	480
TMEM47	GJC1	P36383	452
TMEM47	TMEM178A	Q8NBL3	449
TMEM47	ZNF227	Q86WZ6	447
TMEM47	CNTN5	O94779	446
TMEM47	ANXA3	P12429	442
TMEM47	JTB	O76095	441
TMEM47	GDAP1L1	Q96MZ0	438
TMEM47	CPXM1	Q96SM3	429
TMEM47	TMEM183A	Q8IXX5	418
TMEM47	TMEM176A	Q96HP8	412

IntAct

17 interactions, top by confidence:

A	B	Type	Score
SUSD3	TMEM47	psi-mi:“MI:0915”(physical association)	0.560
FAM209A	TMEM47	psi-mi:“MI:0915”(physical association)	0.560
TMEM179B	TMEM47	psi-mi:“MI:0915”(physical association)	0.560
TMEM47	SPACA1	psi-mi:“MI:0915”(physical association)	0.560
HTT	TMEM47	psi-mi:“MI:0915”(physical association)	0.560
TMEM47	SYNGR2	psi-mi:“MI:0914”(association)	0.350
TMEM47	SUSD3	psi-mi:“MI:0915”(physical association)	0.000
TMEM47	FAM209A	psi-mi:“MI:0915”(physical association)	0.000
TMEM47	TMEM179B	psi-mi:“MI:0915”(physical association)	0.000
TMEM47	SPACA1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (9): TMEM47 (Two-hybrid), TMEM47 (Two-hybrid), SUSD3 (Two-hybrid), TMEM179B (Two-hybrid), AGTRAP (Affinity Capture-MS), CLCN7 (Affinity Capture-MS), CD63 (Affinity Capture-MS), SYNGR2 (Affinity Capture-MS), SNX8 (Affinity Capture-MS)

ESM2 similar proteins: A0A8V0ZLT4, B3VSC2, B5X3I6, F7BWT7, O35566, O60636, O60637, O95857, O95858, P21926, P40239, P40240, P40241, P48509, P61170, P61171, Q06AA5, Q1JPA3, Q1RMP9, Q3SZR9, Q3ZBH3, Q3ZBV0, Q4R4I5, Q58CY8, Q5FVL6, Q5RE11, Q5ZML7, Q6DCQ3, Q6GMK6, Q6GR34, Q6IP19, Q6PBE5, Q6PFT6, Q6QRN8, Q6ZVK1, Q7SZ07, Q80WR1, Q8BHH9, Q8C784, Q8IZV2

Diamond homologs: E9QHT9, Q1JPA3, Q6IP19, Q6PBE5, Q6PFT6, Q96FX8, Q9BQJ4, Q9JJG6, Q9JK95, Q9XSV3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

26 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	9
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1703583	GRCh37/hg19 Xp22.33-11.21(chrX:168546-57841304)	Pathogenic
242889	NM_031442.4(TMEM47):c.35G>C (p.Arg12Pro)	Likely pathogenic

SpliceAI

427 predictions. Top by Δscore:

Variant	Effect	Δscore
X:34630492:C:CC	acceptor_gain	1.0000
X:34639246:CCTG:C	donor_gain	1.0000
X:34639388:C:CC	acceptor_gain	1.0000
X:34640788:T:TA	donor_gain	1.0000
X:34640789:C:A	donor_gain	1.0000
X:34630487:AACAA:A	acceptor_gain	0.9900
X:34630488:ACAA:A	acceptor_gain	0.9900
X:34630489:CAA:C	acceptor_gain	0.9900
X:34630489:CAAC:C	acceptor_gain	0.9900
X:34630490:AA:A	acceptor_gain	0.9900
X:34639241:GTTTA:G	donor_loss	0.9900
X:34639242:TTTA:T	donor_loss	0.9900
X:34639243:TTA:T	donor_loss	0.9900
X:34639244:TA:T	donor_loss	0.9900
X:34639245:AC:A	donor_loss	0.9900
X:34639246:CCT:C	donor_loss	0.9900
X:34639384:CAAT:C	acceptor_gain	0.9900
X:34639386:ATC:A	acceptor_loss	0.9900
X:34639388:C:CG	acceptor_loss	0.9900
X:34656803:CCG:C	donor_gain	0.9900
X:34639247:C:A	donor_loss	0.9800
X:34639385:AAT:A	acceptor_gain	0.9800
X:34639386:AT:A	acceptor_gain	0.9800
X:34639386:ATCT:A	acceptor_gain	0.9800
X:34640785:ACATC:A	donor_gain	0.9800
X:34640786:CATCC:C	donor_gain	0.9800
X:34639383:CCAAT:C	acceptor_gain	0.9700
X:34639384:CAATC:C	acceptor_gain	0.9700
X:34639385:AATCT:A	acceptor_gain	0.9700
X:34639387:TCTG:T	acceptor_gain	0.9700

AlphaMissense

1155 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:34630365:C:T	G165E	1.000
X:34630377:A:T	I161K	1.000
X:34630387:C:G	G158R	1.000
X:34630390:A:G	W157R	1.000
X:34630390:A:T	W157R	1.000
X:34630405:C:G	G152R	1.000
X:34630413:A:G	F149S	1.000
X:34656903:A:G	W43R	1.000
X:34656903:A:T	W43R	1.000
X:34630362:C:T	G166D	0.999
X:34630363:C:G	G166R	0.999
X:34630366:C:G	G165R	0.999
X:34630366:C:T	G165R	0.999
X:34630377:A:C	I161R	0.999
X:34630386:C:T	G158D	0.999
X:34630395:A:G	L155P	0.999
X:34630398:C:T	G154D	0.999
X:34630399:C:G	G154R	0.999
X:34630402:A:G	Y153H	0.999
X:34630404:C:A	G152V	0.999
X:34630404:C:T	G152D	0.999
X:34630406:C:A	W151C	0.999
X:34630406:C:G	W151C	0.999
X:34630408:A:G	W151R	0.999
X:34630408:A:T	W151R	0.999
X:34630412:G:C	F149L	0.999
X:34630412:G:T	F149L	0.999
X:34630413:A:C	F149C	0.999
X:34630414:A:G	F149L	0.999
X:34630448:G:C	F137L	0.999

dbSNP variants (sampled 300 via entrez): RS1000157726 (X:34633699 C>G,T), RS1000233202 (X:34642577 C>T), RS1000668717 (X:34642389 A>C), RS1000797007 (X:34634016 C>T), RS1000844074 (X:34654000 GCTGA>G), RS1000884802 (X:34658505 T>A), RS1001001742 (X:34643781 G>A), RS1001146336 (X:34631619 T>C), RS1001339964 (X:34654386 T>G), RS1001516535 (X:34634975 C>T), RS1001588629 (X:34634525 C>T), RS1001623110 (X:34648084 G>T), RS1001958322 (X:34645868 A>T), RS1001997937 (X:34658440 C>A), RS1002009085 (X:34646429 T>C)

Disease associations

OMIM: gene MIM:300698 | disease phenotypes: MIM:220200

GenCC curated gene-disease

Mondo (3): Turner syndrome (MONDO:0019499), attention deficit-hyperactivity disorder (MONDO:0007743), Dandy-Walker syndrome (MONDO:0009072)

Orphanet (2): Turner syndrome (Orphanet:881), Isolated Dandy-Walker malformation (Orphanet:217)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001860_13	Multiple sclerosis	9.000000e-07
GCST009391_1071	Metabolite levels	8.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010364	lysophosphatidylcholine 20:5 measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D003616	Dandy-Walker Syndrome	C10.228.140.252.300; C10.228.140.602.500; C10.500.205; C16.131.666.205
D014424	Turner Syndrome	C12.050.351.875.253.309.872; C12.050.351.875.253.795.750; C12.200.706.316.309.872; C12.200.706.316.795.750; C12.800.316.309.872; C12.800.316.795.750; C14.240.400.980; C14.280.400.980; C16.131.240.400.970; C16.131.260.830.835.750; C16.131.939.316.309.872; C16.131.939.316.795.750; C16.320.180.830.835.750; C19.391.119.309.872; C19.391.119.795.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, decreases expression	3
Estradiol	affects expression, affects cotreatment, decreases expression	3
bisphenol A	decreases expression, increases expression, increases methylation	2
Acetaminophen	increases expression	2
Nickel	decreases expression	2
Progesterone	decreases expression, increases expression, affects cotreatment	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression, increases expression	2
sodium arsenite	increases expression	1
cobaltous chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
diallyl trisulfide	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
(+)-JQ1 compound	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Decitabine	decreases expression, decreases reaction	1
Sunitinib	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Allergens	decreases expression	1
Benzo(a)pyrene	increases methylation, affects methylation	1
Camptothecin	increases expression	1
Carbamazepine	affects expression	1
Cisplatin	increases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Doxorubicin	decreases expression	1
Etoposide	affects response to substance	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00134745	PHASE4	COMPLETED	Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome
NCT00256126	PHASE4	COMPLETED	Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
NCT00266656	PHASE4	COMPLETED	Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01245374	PHASE4	COMPLETED	Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
NCT01419249	PHASE4	COMPLETED	First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study
NCT01518062	PHASE4	COMPLETED	Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
NCT01734486	PHASE4	COMPLETED	Growth Response in Girls With Turner Syndrome
NCT03015909	PHASE4	COMPLETED	Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.
NCT06544473	PHASE4	RECRUITING	Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome
NCT06570460	PHASE4	RECRUITING	Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome
NCT06834594	PHASE4	RECRUITING	Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00181571	PHASE4	COMPLETED	A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder
NCT00181675	PHASE4	COMPLETED	A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder
NCT00181714	PHASE4	COMPLETED	Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta
NCT00181948	PHASE4	COMPLETED	Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
NCT00181987	PHASE4	COMPLETED	Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder
NCT00190736	PHASE4	COMPLETED	Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)
NCT00190775	PHASE4	COMPLETED	A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00190879	PHASE4	COMPLETED	Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
NCT00190957	PHASE4	COMPLETED	Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
NCT00191035	PHASE4	COMPLETED	Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
NCT00191048	PHASE4	COMPLETED	Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
NCT00191633	PHASE4	COMPLETED	Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes
NCT00191906	PHASE4	COMPLETED	Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
NCT00216918	PHASE4	COMPLETED	Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.
NCT00221962	PHASE4	COMPLETED	Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)
NCT00223561	PHASE4	COMPLETED	Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder
NCT00299234	PHASE4	TERMINATED	Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL
NCT00302406	PHASE4	COMPLETED	Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate
NCT00305370	PHASE4	COMPLETED	Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD
NCT00381758	PHASE4	COMPLETED	The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting
NCT00406354	PHASE4	COMPLETED	Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany
NCT00434213	PHASE4	COMPLETED	Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
NCT00468143	PHASE4	COMPLETED	A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
NCT00471354	PHASE4	COMPLETED	A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
NCT00483106	PHASE4	COMPLETED	Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
NCT00485849	PHASE4	COMPLETED	A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD
NCT00485875	PHASE4	COMPLETED	Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD